BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. These EGFR-dependent tumors eventually become TKI resistant, and the common s...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Daniel B, Halmos, Balázs, Kumar, Amit, Schumer, Susan T, Huberman, Mark S, Boggon, Titus J, Tenen, Daniel G, Kobayashi, Susumu
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043012/
https://www.ncbi.nlm.nih.gov/pubmed/17973572
http://dx.doi.org/10.1371/journal.pmed.0040315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043012/
https://www.ncbi.nlm.nih.gov/pubmed/17973572
http://dx.doi.org/10.1371/journal.pmed.0040315

Ejemplares similares